(Press-News.org) CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
These initial findings from the phase III clinical trial confirm the results of the phase II trial, presented just weeks ago at the American Association of Cancer Research annual meeting in Philadelphia and published by MSK researchers online in NEJM.
Jedd Wolchok, Chief of MSK's Melanoma and Immunotherapeutics Service, designed and led the phase III randomized, double-blind trial, in which 945 patients with untreated advanced melanoma were randomized to receive ipilimumab alone, nivolumab alone, or a combination of the two.
While this study was not designed for a formal statistical comparison between the nivolumab group and the combination group, exploratory analyses revealed more frequent responses and longer PFS in the combination group when compared with nivolumab alone. Patients receiving the combination experienced a median PFS of 11.5 months, while median PFS for patients receiving nivolumab alone was 6.9 months and ipilimumab alone was 2.9 months.
Of the 314 patients receiving the combination, 57.6 percent had an objective response, measured as a significant reduction in tumor size, versus 43.7 percent of the 316 receiving nivolumab alone and 19 percent of the 315 receiving ipilimumab alone.
"All the early preclinical and clinical work supported the idea that combining these two immunotherapy drugs could result in better outcomes for patients," said Dr. Wolchok. "We're encouraged by the progression-free survival data we're currently reporting. It is a testament to how drastically immunotherapy has altered the prognostic landscape for some advanced melanoma patients. Just five years ago, many of these patients would have been expected to live for only seven months following diagnosis -- but it's important to remember that overall survival data for this group is not yet available."
Adverse side effects such as diarrhea and increased lipase occurred in 55 percent of patients receiving the combination -- leading about one-third of these patients to stop the regimen. About 16 percent of patients receiving nivolumab alone and 27 percent of patients receiving ipilimumab alone experienced side effects, with nearly 8 percent and 15 percent of patients discontinuing, respectively.
Ipilimumab and nivolumab are part of a class of drugs called immune checkpoint inhibitors, which unleash patients' immune system to attack their cancer. The immune system has several checkpoints in place to avoid an overreaction. Ipilimumab works by blocking the CTLA-4 checkpoint, a molecular brake that stops T cells from becoming fully and persistently activated. Similarly, nivolumab prevents the molecule PD-L1, expressed by tumors, from binding to T cells and deactivating them.
Notably in this trial, patients whose tumors expressed PD-L1 experienced a median PFS of 14 months regardless of whether they received the combination or nivolumab alone, but for patients whose tumors did not express PD-L1, the median PFS was longer on the combination (11.2 months) than on nivolumab alone (5.3 months).
"One of the biggest questions in the field of immunotherapy has been how to determine which patients will respond to immune-modulating drugs. Now we have another piece of data," said Dr. Wolchok. "A simple pathology test can identify patients whose tumors express PD-L1, and this information will help the patient and physician decide whether to use the combination or nivolumab alone, knowing the toxicity risks and the difference in PFS. However, if a patient's tumor does not express PD-L1, the data suggests it makes more sense to offer the combination. This understanding gets us closer to 'precision immunotherapy.'"
Dr. Wolchok, who is also the Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK, designed this clinical trial on a napkin at the 2012 ASCO annual meeting ¬before the data from the phase I trial were even presented.
"Even then, we knew the potential that immunotherapy could have for the lives of patients diagnosed with advanced melanoma and other cancers," he said. "As we present this exciting and hopeful data to the international oncology community, we pause and thank the patients who enrolled in this -- and all -- clinical trials. These individuals are blazing the trails of cancer research, and we are indebted to them for helping to better the care of patients for generations to come."
INFORMATION:
About Memorial Sloan Kettering
We are the world's oldest and largest private cancer center, home to more than 13,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to http://www.mskcc.org.
New Haven, Conn. -- Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.
Nearly 300,000 women in the United States are diagnosed with breast cancer each year; more than half undergo breast-conserving surgery with a partial mastectomy to remove the disease. However, between 20% and 40% of patients ...
CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Investigators further found that pacritinib could be used safely in patients with myelofibrosis who ...
CHICAGO -- Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.
Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone.
The announcement was made at ...
Alexandria, VA - As this summer's blockbuster movie season gets underway, EARTH Magazine asks an important question: In movies, "are geologists portrayed as heroes or villains?" The topic of how geologists are portrayed in film has been oft-debated around a campfire, or over a frosty beverage at the end of a day of fieldwork, but now four scientists bring some serious analysis to the subject in the June issue feature, "Rock Stars - Geologists on the Silver Screen."
The authors - all geologists in the Department of Earth Sciences at the University of Gothenburg in Sweden ...
Hercules, CA -- May 29, 2015 -- Researchers at Harvard Medical School and the Digital Biology Center at Bio-Rad Laboratories, Inc. have developed a rapid, scalable, and cost-effective method for chromosomal phasing that provides researchers with a new method to determine if genetic variants are linked on the same chromosome. Using Bio-Rad's Droplet Digital PCR (ddPCRTM) technology, the Drop-Phase method can rapidly determine the chromosomal phase of allelic markers hundreds of kilobases apart. This ability may provide new insights into the cause, penetrance, and severity ...
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
Results of the trial with pembrolizumab, marketed as Keytruda, ...
The recent floods in Texas have caused some of the worst flooding since Hurricane Ike in 2008, causing the rainiest month in the state's history.
What lessons have been learned from Ike's devastation of the Galveston and Houston area, and how have they helped in the prediction of future such storms?
Researchers at the Institute for Computational Engineering and Sciences at the University of Texas at Austin have been studying computational models and simulations of hurricanes like Ike in order to predict the consequences of such natural disasters and better prepare ...
PHOENIX -- If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined.
In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.
One of the most common reasons people ...
At a traditional stone-laying ceremony outside La Serena, Chile on April 14th, construction officially began of the Large Synoptic Survey Telescope (LSST). This ambitious international astrophysics project is slated to start scanning the heavens in 2022. When it does, LSST should open up the "dark universe" of dark matter and dark energy--the unseen substance and force, respectively, composing 95 percent of the universe's mass and energy--as never before.
On April 2, 2015, the Director of LSST, Steven Kahn, along with astrophysicist Sarah Bridle and theoretical physicist ...
The study, published May 29 in the open access Nature Publishing Group journal Scientific Reports, reveals a direct link between the main culprit of Alzheimer's disease and memory loss.
Alzheimer's disease is characterized by the formation of amyloid plaques in the brain tissue. These amyloid plaques are made up of an insoluble protein, 'Amyloid-beta' (Abeta), which forms small structures called 'oligomers' that are important in the disease progression.
Although these proteins are known to be involved in Alzheimer's, little is understood about how they lead to memory ...
